These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 21502077)

  • 1. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
    Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
    Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.
    Gioria S; Caputo F; Urbán P; Maguire CM; Bremer-Hoffmann S; Prina-Mello A; Calzolai L; Mehn D
    Nanomedicine (Lond); 2018 Mar; 13(5):539-554. PubMed ID: 29381129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology versus other techniques in improving drug dissolution.
    Kwok PC; Chan HK
    Curr Pharm Des; 2014; 20(3):474-82. PubMed ID: 23651399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections.
    Lembo D; Donalisio M; Civra A; Argenziano M; Cavalli R
    Expert Opin Drug Deliv; 2018 Jan; 15(1):93-114. PubMed ID: 28749739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
    Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
    Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Patent Review of Nanoparticles in Drug Delivery and Cancer Therapy in the Last Decade.
    Ali Hazis NU; Aneja N; Rajabalaya R; David SR
    Recent Adv Drug Deliv Formul; 2021; 15(1):59-74. PubMed ID: 34602031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical hazard evaluation strategy for nanomedicines.
    Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
    Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators.
    Yang Y; Zhang M; Song H; Yu C
    Acc Chem Res; 2020 Aug; 53(8):1545-1556. PubMed ID: 32667182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
    Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
    Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in development of nanoparticle-based therapeutics.
    Desai N
    AAPS J; 2012 Jun; 14(2):282-95. PubMed ID: 22407288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
    Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
    Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.